Fox Run Management L.L.C. Raises Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Fox Run Management L.L.C. lifted its stake in shares of Twist Bioscience Co. (NASDAQ:TWST) by 57.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 16,739 shares of the company’s stock after purchasing an additional 6,138 shares during the quarter. Fox Run Management L.L.C.’s holdings in Twist Bioscience were worth $778,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Massachusetts Financial Services Co. MA raised its stake in shares of Twist Bioscience by 215.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 29,314 shares of the company’s stock valued at $1,324,000 after purchasing an additional 20,035 shares during the period. Barclays PLC raised its stake in shares of Twist Bioscience by 214.8% during the 3rd quarter. Barclays PLC now owns 153,039 shares of the company’s stock valued at $6,913,000 after purchasing an additional 104,420 shares during the period. FMR LLC raised its stake in shares of Twist Bioscience by 6.0% during the 3rd quarter. FMR LLC now owns 218,561 shares of the company’s stock valued at $9,875,000 after purchasing an additional 12,327 shares during the period. Avanza Fonder AB bought a new stake in shares of Twist Bioscience during the 4th quarter valued at $1,059,000. Finally, BNP Paribas Financial Markets raised its stake in shares of Twist Bioscience by 128.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 38,032 shares of the company’s stock valued at $1,718,000 after purchasing an additional 21,357 shares during the period.

Insider Activity at Twist Bioscience

In related news, Director Robert Chess sold 5,000 shares of the stock in a transaction dated Tuesday, January 7th. The stock was sold at an average price of $50.00, for a total transaction of $250,000.00. Following the completion of the sale, the director now directly owns 16,641 shares in the company, valued at $832,050. This represents a 23.10 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Emily M. Leproust sold 5,200 shares of the stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $49.35, for a total value of $256,620.00. Following the completion of the sale, the chief executive officer now owns 667,318 shares of the company’s stock, valued at approximately $32,932,143.30. This trade represents a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 31,552 shares of company stock worth $1,500,289 in the last ninety days. 3.01% of the stock is owned by company insiders.

Twist Bioscience Trading Up 2.0 %

Shares of TWST stock opened at $42.89 on Monday. The stock has a market capitalization of $2.56 billion, a PE ratio of -12.69 and a beta of 2.15. Twist Bioscience Co. has a 1-year low of $27.41 and a 1-year high of $60.90. The business has a 50-day moving average of $45.40 and a 200 day moving average of $45.27. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST) last issued its earnings results on Monday, February 3rd. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.62) by $0.09. The company had revenue of $88.70 million during the quarter, compared to analysts’ expectations of $86.96 million. Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. Twist Bioscience’s quarterly revenue was up 24.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.75) EPS. As a group, sell-side analysts anticipate that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of research analyst reports. JPMorgan Chase & Co. upped their target price on Twist Bioscience from $35.00 to $40.00 and gave the stock an “underweight” rating in a research note on Tuesday, February 4th. Barclays set a $58.00 target price on Twist Bioscience and gave the stock an “overweight” rating in a research note on Monday, February 3rd. TD Cowen restated a “buy” rating and issued a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Scotiabank reiterated an “outperform” rating on shares of Twist Bioscience in a report on Tuesday, February 4th. Finally, Robert W. Baird upped their price objective on Twist Bioscience from $48.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $54.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.